Achieve life sciences reports financial results for second quarter 2023 and provides corporate update

Company to host conference call tomorrow, tuesday, august 15, 2023, at 8:30 am edt seattle and vancouver, british columbia, aug. 14, 2023 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. recent highlights publication of phase 3 orca-2 trial results in the journal of the american medical association (jama) reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory phase 3 orca-3 trial announced phase 2 orca-v1 trial results showing statistically significant vaping cessation benefit with cytisinicline treatment closed equity financing with gross proceeds of approximately $16.5 million, prior to deducting placement agent commissions and estimated offering expenses refinanced outstanding loan with silicon valley bank (svb) "we've had a very exciting and eventful first half of 2023, with two additional clinical trials reading out with positive results for cytisinicline in both smoking and vaping cessation, and the recent publication of the completed phase 3 orca-2 trial in the highly prestigious journal of the american medical association,” commented john bencich, ceo of achieve.
ACHV Ratings Summary
ACHV Quant Ranking